From: Jeffrey Epstein <jeffreyepsteinorg®gmail.com> To: "Ting, Jess" Cc: Jeffrey Epstein <jeevacation®gmail.com> Subject: Re: media for Jeffrey Epstein's Foundation Date: Tue, 12 Mar 2013 02:57:11 +0000 Dear Mr. Tess, Thank you so much for drafting a basis for a press release. I think the text will be sufficient for me to piece something together. I will send a draft out to you by the end of tomorrow for you to review and approve. On Mon, Mar 11, 2013 at 3:27 PM, Ting, Jess < > wrote: Hi The text below is what we came up that you could use for a press release. It outlines the research without giving away our secrets. What do you think? Clinical analysis of blood is one the most frequently used body fluid assays. Blood is a rich source of disease- related biomarkers. However, the complexity of the composition of human blood, combined with its large volume, and therefore the dilution of potential biomarkers to undetectable levels, represent major challenges and limitations to the use of blood for biomarker assays. As an alternative, researchers have expanded the search for disease-specific biomarkers to other body fluids, including urine, cerebrospinal fluid, bronchoalveolar lavage fluid, synovial fluid, nipple aspirate fluid, tear fluid, aminotic fluid and seminal plasma. In relation to cancer more specifically, much attention has been paid to the analysis of interstitial fluids in cancer patients. This fluid, when found in the abdominal cavity, is referred as ascites and when found around the lungs, is referred as pleural effusion fluid. However, these fluids are only informative in advanced metastatic cancer patients and therefore their prognostic value in term of disease progression is limited. A Mount Sinai team led by a surgeon, Dr. Jess Ting, a breast oncologist, Dr. Kerin Adelson and a molecular biologist, Dr. Doris Germain, is currently evaluating the use of on an up-to-now largely overlooked body fluid, post-surgical wound fluid. Sur